Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Journal of Pharmaceutical Policy and Practice

Fig. 1

From: Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

Fig. 1

Probability of new indication exclusivity granted by FDA for drugs approved, 1997–2020. The probability of a new indication addition is highest when NMEs have been relatively recently (within 1–2 years) and when generic entry is around 7–8 years into the future. The probability is lowest when an NME has been approved for more than 15 years and when generic entry has already occurred. “Age (in years)” = number of years since FDA approval

Back to article page

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us